1. Home
  2. RZLT vs LUNG Comparison

RZLT vs LUNG Comparison

Compare RZLT & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RZLT
  • LUNG
  • Stock Information
  • Founded
  • RZLT 2010
  • LUNG 1995
  • Country
  • RZLT United States
  • LUNG United States
  • Employees
  • RZLT N/A
  • LUNG N/A
  • Industry
  • RZLT Biotechnology: Pharmaceutical Preparations
  • LUNG Industrial Specialties
  • Sector
  • RZLT Health Care
  • LUNG Health Care
  • Exchange
  • RZLT Nasdaq
  • LUNG Nasdaq
  • Market Cap
  • RZLT 819.3M
  • LUNG 63.6M
  • IPO Year
  • RZLT N/A
  • LUNG 2020
  • Fundamental
  • Price
  • RZLT $9.32
  • LUNG $2.00
  • Analyst Decision
  • RZLT Strong Buy
  • LUNG Buy
  • Analyst Count
  • RZLT 7
  • LUNG 7
  • Target Price
  • RZLT $14.86
  • LUNG $6.81
  • AVG Volume (30 Days)
  • RZLT 1.4M
  • LUNG 6.3M
  • Earning Date
  • RZLT 11-07-2025
  • LUNG 11-12-2025
  • Dividend Yield
  • RZLT N/A
  • LUNG N/A
  • EPS Growth
  • RZLT N/A
  • LUNG N/A
  • EPS
  • RZLT N/A
  • LUNG N/A
  • Revenue
  • RZLT N/A
  • LUNG $90,549,000.00
  • Revenue This Year
  • RZLT N/A
  • LUNG $10.30
  • Revenue Next Year
  • RZLT N/A
  • LUNG $14.72
  • P/E Ratio
  • RZLT N/A
  • LUNG N/A
  • Revenue Growth
  • RZLT N/A
  • LUNG 18.24
  • 52 Week Low
  • RZLT $2.22
  • LUNG $1.47
  • 52 Week High
  • RZLT $10.04
  • LUNG $9.37
  • Technical
  • Relative Strength Index (RSI)
  • RZLT 55.19
  • LUNG 60.35
  • Support Level
  • RZLT $9.00
  • LUNG $1.72
  • Resistance Level
  • RZLT $9.89
  • LUNG $2.89
  • Average True Range (ATR)
  • RZLT 0.59
  • LUNG 0.19
  • MACD
  • RZLT 0.01
  • LUNG 0.04
  • Stochastic Oscillator
  • RZLT 68.24
  • LUNG 35.04

About RZLT Rezolute Inc. (NV)

Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.

Share on Social Networks: